close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

763.06 +14.35 (+1.92%)
Streaming Delayed Price Updated: 11:35 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
58 59 Next >
News headline image
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years ↗
It might not be too late to invest in these impressive growth stocks. 
Via The Motley Fool
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
News headline image
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector ↗
 
Via Benzinga
News headline image
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts ↗
 
Via Benzinga
News headline image
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry ↗
 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
From Kirby McInerney LLP
Via Business Wire
News headline image
Regeneron Earnings Miss; Biotech Giant's Stock Falls ↗
The biotech giant's earnings and sales both missed Q1 estimates. 
Via Investor's Business Daily
News headline image
These 2 No-Brainer Growth Stocks Are Breaking New Ground ↗
The future keeps getting brighter for these companies. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Week Of May 13, 2024: What's In Store For The Markets ↗
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch. 
Via Talk Markets
News headline image
Healthcare And Biotech Investing 101: What You Need To Know. ↗
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
News headline image
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sell In May? No Way! ↗
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away. 
Via Talk Markets
News headline image
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
News headline image
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
News headline image
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review ↗
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
News headline image
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar ↗
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains. 
Via InvestorPlace
News headline image
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation ↗
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%. 
Via Benzinga
News headline image
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday? ↗
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains. 
Via Benzinga
Topics Economy
News headline image
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗
REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond ↗
It pays to develop novel medicines for life-threatening illnesses. 
Via The Motley Fool
News headline image
Regeneron Reports First Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today